Skip to content

Brain Imaging of Cognition Inn Schizophrenia and Depression

Brain Imaging of Cognition Inn Schizophrenia and Depression

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04159662
Enrollment
90
Registered
2019-11-12
Start date
2019-12-12
Completion date
2026-10-01
Last updated
2026-03-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Depression / Major Depressive Disorder, Schizophrenia / Schizoaffective Disorder

Brief summary

Schizophrenia and depression are among the most disabling disorders in all of medicine. Cognitive deficits play a key role in patients' disability, affecting their capacity to contribute actively to society by sustaining employment or academic activity. Moreover, cognitive difficulties tend to persist even after the stabilization of other clinical symptoms. Verbal memory and emotion regulation are two important cognitive domains that are impaired in schizophrenia and depression and are associated with patients' functional outcomes. In this study, brain imaging is used to investigate the brain mechanisms underlying these cognitive deficits in these populations.

Detailed description

This study uses Functional Magnetic Resonance Imaging (fMRI) which is a technique that takes a 3D picture of the brain using magnetic fields. It allows researchers to estimate how active different regions of the brain are. The aim of this study is to use fMRI to better understand the cognitive problems that individuals living with schizophrenia, schizoaffective disorder, or depression experience. The study will involve three visits at The Royal's Institute of Mental Health Research in Ottawa, Canada. Each visit will last about 2.5 hours long. Visits 1 and 2: Participants are asked to fill out several questionnaires on a computer. Participants are also asked to answer some questions about their current and past mental health as well as perform some tasks involving general thinking skills. Visit 3: Participants will complete a brain scan using fMRI. Throughout the experiment, participants will perform three short tasks in the fMRI scanner. Participants will use buttons to answer some questions in response to some words and pictures.

Interventions

None listed

Sponsors

The Royal Ottawa Mental Health Centre
Lead SponsorOTHER

Study design

Observational model
OTHER
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
No

Inclusion criteria

* age 18-60 years * current Intelligence Quotient (IQ) \> 70 as measured by the Wechsler Abbreviated Scale of Intelligence (WASI) * the ability to read and speak fluent English * a diagnosis of schizophrenia, schizoaffective or major depression disorder * stable medication for more than one month

Exclusion criteria

* significant neurological or other medical disorders that may produce cognitive impairment * a recent history of substance abuse or dependence (within the past 3 months) * any magnetic resonance imaging (MRI) contraindications (e.g. metallic head implant, history of seizure, pacemaker) * decisional incapacity requiring a guardian * taking medications that are rated as Anticholinergic Burden (ACB) Score 3 (severe) or taking benzodiazepines on a daily basis * Finally, participants could not be severely symptomatic at the time of study enrolment to ensure that they could understand and complete all study assessments. This criterion was defined as a score ≤34 on the Montgomery-Åsberg Depression Rating Scale (MADRS; Montgomery \& Åsberg, 1979) for the MDD group and a score ≤95 on the Positive and Negative Syndrome Scale (PANSS; Kay et al., 1987) for the SZ group.

Design outcomes

Primary

MeasureTime frameDescription
Measuring brain activity using resting-state and task-based functional MRIFinal Visit (Visit 3)To better understand the mechanisms underlying cognitive problems in our populations of interest

Countries

Canada

Contacts

CONTACTSynthia Guimond, PhD
Synthia.Guimond@theroyal.ca6137226521
PRINCIPAL_INVESTIGATORSynthia Guimond, PhD

Royal Ottawa Mental Health Centre

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 24, 2026